In an unexpected move, Bausch Health recently stopped participating in Medicaid and a federal government drug discount scheme known as 340B, a step that suggests more drugmakers may rethink decisions to provide their medicines to these widely used programs.
Bausch disclosed its decision in a brief statement on its website but did not offer an explanation. A spokeswoman said the company “remains fully committed” to patients who are prescribed its medicines and to compensate a patient assistance program was “enhanced” with zero out-of-pocket costs for covered medicines and free home delivery.
The change, which went into effect on Oct. 1, comes as the pharmaceutical industry is under increased pressure from the Trump administration to lower prices and is confronting various changes that affect the calculus used to set prices. This is especially true when it comes to Medicaid.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply